{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-002750","form_type":"8-K","ticker":"TOVX","cik":"0000894158","company_name":"Theriva Biologics, Inc.","filed_at":"2026-01-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.971901+00:00","generated_at":"2026-05-16T11:00:12.044109+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"confidence":"low","headline":"Theriva Biologics announces investor presentations with updated corporate deck","bullets":["Company to present to investors over next several weeks; updated deck filed as Exhibit 99.1.","Presentation titled 'Unique Oncolytic Virus Therapies for Multiple Solid Tumors' dated Jan 2026.","CEO Steven Shallcross signed the filing; stock trades on NYSE American under TOVX.","No specific financial or clinical data disclosed in the filing or exhibit text provided."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-002750","json":"https://secwatch.observer/filing/0001104659-26-002750.json","markdown":"https://secwatch.observer/filing/0001104659-26-002750.md","text":"https://secwatch.observer/filing/0001104659-26-002750.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/894158/000110465926002750/0001104659-26-002750-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/894158/000110465926002750/tm262896d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:00:12.044109+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}